Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Shriners Children’s Northern California Becomes Second in Nation to Achieve Highest Level of Musculoskeletal Surgical Verification


Shriners Children's doctor and patient doing orthopedic visit

Maya Evans, M.D., conducting a physical medicine and rehabilitation visit with a patient.

“This Level I verification is extremely meaningful to us at Shriners Children’s, because it reflects our continual efforts to provide high-quality care to more children, closer to where they live.”

Shriners Children’s Northern California is the second pediatric hospital in the nation to obtain verification as a Level I Specialty Children’s Surgery-Musculoskeletal Surgery Center by the American College of Surgeons (ACS), and the only facility on the west coast. The Level I verification is the highest of 3 levels of ACS surgical verification a pediatric hospital can receive.

Level I Specialty Children’s Surgery-Musculoskeletal verification requires pediatric hospitals to meet strict standards, demonstrating that patients receiving surgery receive care under a multidisciplinary program while ensuring safety standards and processes, meticulous data collection, high quality improvement and appropriate surgical resources. The verification followed an extensive review of hospital structure, processes, and outcomes conducted by a team of ACS surveyors including experienced pediatric surgeons, anesthesiologists and nurses.

“This Level I verification is extremely meaningful to us at Shriners Children’s, because it reflects our continual efforts to provide high-quality care to more children, closer to where they live,” said Jerry G. Gantt, Shriners Children’s Chairman of the Board of Trustees. “We are committed to providing hope and healing to the patients who come to Shriners Children’s Northern California for surgical services.”

The Shriners Hospitals for Children healthcare system has a long history of delivering exceptional pediatric care, through its three-part mission of caring for patients with the highest quality care, conducting research to gain knowledge and develop new treatments and providing educational opportunities for physicians and the next generation of healthcare professionals.

“We are honored to be only one of two pediatric hospitals in the nation with this verification,” said Chief of Orthopedics, Michelle James, MD. “This verification from the American College of Surgeons reflects our organization’s commitment to providing individualized, patient-centered, high-quality care and experience for the families we serve. It confirms to parents and healthcare professionals that, for their children and patients, the highest level of musculoskeletal care available in the nation can be received here.”

Shriners Children’s Northern California is ranked by U.S. News and Report as one of the top orthopedics program in the country, in partnership with UC Davis Children’s Hospital. Shriners Children’s Northern California’s signature clinical programs within orthopedics includes fracture follow-up and care, hand and upper extremity program, lower extremity care, multidisciplinary neuromuscular programs, spine and scoliosis care and sports medicine. Patients receive care from a multi-disciplinary team of surgeons, anesthesiologists, nurse practitioners, psychiatrists and psychologists, burn technicians, occupational and physical therapists, nutritionists, social workers, pharmacists, child life specialists and orthotists. Shriners Children’s continues to serve on their mission of treating any patient who qualifies for care regardless of their ability to pay or insurance status.

About Shriners Children’s:

Shriners Children’s is changing lives every day through innovative pediatric specialty care, world-class research and outstanding medical education. Our multiple locations in the United States, Canada and Mexico provide advanced care for children with orthopedic conditions, burns, spinal cord injuries, and cleft lip and palate. All care is provided regardless of the families’ ability to pay. Shriners Children’s has treated more than 1.5 million children from more than 170 countries over the last 100 years.

For more information on the care provided by Shriners Children’s, go to shrinerschildrens.org

Shriners Hospitals for Children is a 501(c)(3) nonprofit organization and relies on the generosity of donors. All donations are tax deductible to the fullest extent permitted by law.

Share article on social media or email:

Air Animal Recommends Canine Flu Vaccine Before Relocation, Travel or Dog Groomer Visits


Two pups out for a social day at the Dog Days of Summer Concert. Photo by Thompson Brand Images.

Social pups should be vaccinated for canine influenza. It’s highly contagious between dogs. Dog flu can cause pneumonia and death.

A canine influenza outbreak is spreading across the southern U.S.—Tennessee, Texas. South Carolina, Alabama and elsewhere. It can quickly spread around the world because more people now travel and relocate with their pets. Air Animal urges all dog parents to vaccinate their dogs against canine influenza before relocating, traveling or any visit outside the home.

“People take their dogs with them everywhere today,” warns Walter M. Woolf, VMD, founding veterinarian and CEO at Air Animal Pet Movers. “Going to the dog park, the veterinarian, the dog groomer or doggie daycare can expose your precious fur baby to canine influenza. Flu in dogs is potentially dangerous and very contagious. It does not currently pose a risk for people.”

Like flu in humans, canine influenza is spread through aerosols and respiratory droplets.

“Dog flu is easily prevented by vaccinating your dog with two doses of the canine flu vaccine,” Woolf explained. “Ask your veterinarian about the vaccine. The first shot provides partial immunity. The second shot given about two weeks later is a booster which gives stronger protection.”

There are two types of canine influenza vaccines. Ask your veterinarian which she recommends.

  • Zoetis – Vanguard CIV H3N2/H3N8 – 2 vaccinations, 3 weeks apart. Considered fully vaccinated 7 days after the second shot.
  • Merck – Nobivac CIV H3N2/H3N8 – 2 vaccinations, 2 weeks apart. Considered fully vaccinated 14 days after the second shot.

For people relocating overseas with their dogs, New Zealand, Australia and other countries now require dog flu vaccination, according to Woolf. These countries usually accept a recent booster shot if the documents show full previous immunization and the booster administration date.

Dogs that come down with the flu develop fevers and coughs that last one to three weeks. Dog parents may notice decreased appetite, lethargy and a greenish discharge from the nose and eyes. Some dogs develop higher fevers and pneumonia. Severe dog flu cases cause death.

For people traveling or taking their dogs anywhere outside the home–especially to an overseas destination—canine flue vaccination is an ounce of prevention that really is better than a pound of cure.

Learn more about country requirements for importing pets at airanimal.com.

About Air Animal

Air Animal has helped more than 55,000 families move their 135,000 furry, feathered and scaly pets around the globe since 1977. They welcome pet move authorizations and referrals from major corporations, relocation management agencies, household goods movers, veterinarians, families, U.S. military and government transferees. Get the best in animal care and transportation. Air Animal is an appointed and endorsed IATA air cargo sales agency working with all airlines that move animals. They are an Indirect Air Carrier cleared for tendering live animals to airlines by the U.S. Transportation Security Administration. See airanimal.com to learn more about Pet Moving Made Easy®.

Share article on social media or email:

11th Chief Medical Officer Summit 360° Agenda and Keynotes Announced from The Conference Forum


The two-day CMO Summit has over 60 biotech Chief Medical Officers speaking in over 40 sessions. We are grateful to the support of this incredible community of R&D leadership representing biotechs of all therapeutic areas.

The Conference Forum is pleased to announce the agenda and keynote speakers for the 11th annual Chief Medical Officer Summit 360°, the only conference dedicated to supporting the role of the Chief Medical Officer in emerging biotechs. The CMO Summit 360° will take place in Boston on April 4-5.

“The two-day CMO Summit has over 60 biotech Chief Medical Officers speaking in over 40 sessions. We are grateful to the support of this incredible community of R&D leadership representing biotechs of all therapeutic areas,” says Andrew Goldstein, Senior Conference Producer for the CMO Summit 360°.

Dr John Maraganore, Founding CEO of Alnylam Pharmaceutical is the CEO keynote. Dr Maraganore will share highlights and lessons learned from his 19 years as a CEO leading a team that conquered some very difficult drug development challenges and how he worked with his senior level R&D leadership.

The state of the drug development industry keynote address will be given by Ken Getz, MBA, Deputy Director of Sponsored Research, Tufts CSDD, and Founder of CISCRP.

The CMO Summit 360°’s Founding Advisor, Dr Elizabeth Stoner, Executive Partner at MPM Capital, will share some opening remarks as well as provide a snapshot on what investors look for in a CMO and the biotech investment landscape.

Additionally, for the first time at the CMO Summit 360°, there will be a series of fireside discussions between CMOs and their C-suite colleagues on how they communicate and collaborate cross-functionally.

Key topic areas for 2023 covered include: biotech finance and business development, trends and technologies in clinical development, regulatory best practices, organizational management, internal relationships and team building, communication strategies, professional development for CMOs and more.

The Chief Medical Officer Summit 360°brings together CMO and R&D executives to address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital and strategizing for appropriate exits. It is the annual Boston gathering for R&D leadership networking from small to mid-size biotechs to share ideas, solutions and support.

To learn more about the event, please visit https://theconferenceforum.org/conferences/chief-medical-officer-summit/overview/

About the Conference Forum:

The Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high-quality networking. Learn more about the Conference Forum at theconferenceforum.org.

Share article on social media or email:

Dallas Plastic Surgeon Dr. Rod J. Rohrich Honored as Texas Monthly Super Doctor


Dallas plastic surgeon Dr. Rod J. Rohrich

Dallas plastic surgeon Dr. Rod J. Rohrich

“Surgeon selection is the single most influential factor for ensuring a successful outcome in plastic surgery.”

Dallas plastic surgeon and rhinoplasty specialist, Dr. Rod J. Rohrich, has been recognized as one of the best plastic surgeons in Texas for 2022 by Texas Monthly’s annual list of outstanding physicians.

The Super Doctor award is granted to exceptional physicians based on nominations by colleagues practicing in their specialty and within their region. The highest rated nominees are then reviewed by a panel of peers based on 10 areas of professional excellence and achievements. These include years of experience, professional honors, board certifications, academic accomplishments, and teaching roles. Candidates are also rated on their involvement in scientific publications, medical research, participation in lectures, and other professional activities.

Based on his extensive ongoing work in these areas, Dr. Rohrich, whose clinical practice focuses on aesthetic plastic surgery such as rhinoplasty, revision rhinoplasty, and facelift surgery, has been designated as a Super Doctor for the 18th consecutive year. According to their website, the Super Doctor award is only granted to approximately the top five percent of regional medical specialists.

“Rigorous awards such as Super Doctors can be a valuable resource for patients who are evaluating their options,” says Dr. Rohrich. “Surgeon selection is the single most influential factor for ensuring a successful outcome in plastic surgery.”

Dr. Rohrich is a longstanding advocate for patient safety and his innovative approach to maximizing both consistency and excellence in both primary and revision rhinoplasty. A significant part of his practice consists of secondary or revision nasal surgeries, often for patients who have had poor results from their primary surgeries. Over half of his rhinoplasty patients in Dallas, for example, come to him seeking revision rhinoplasty – corrective surgery from a previous rhinoplasty that had an unsatisfactory outcome.

“The single most important factor in all of plastic surgery is who you select as your surgeon,” says Dr. Rohrich. “Patients should always do their research and choose their surgeon carefully. Make sure he or she is board certified by a specialty of the American Board of Medical Specialties, and has the expertise and the experience to deliver a safe and satisfactory outcome.” He emphasized the 3 Es for finding the best plastic surgery expert – Experience, Expertise, and the ability to deliver consistently Excellent results.

About Rod J. Rohrich, M.D., F.A.C.S.

Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He is considered one of the most influential surgeons in this century. He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021 and 2022. Dr. Rohrich is a Clinical Professor of Plastic Surgery at Baylor College of Medicine. He was the first Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors, and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.

He is the immediate past (after serving for 18 years) past Editor-in-Chief of the most respected global peer reviewed plastic surgery journal – the Plastic and Reconstructive Surgery Journal. He is Founding Editor-in-Chief/Editor Emeritus of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 1000 peer reviewed articles and seven textbooks in plastic surgery including a best-selling medical book entitled The Facial Danger Zones. Dr. Rohrich recently published an innovative cosmetic surgery video atlas, Cosmetic Surgery by the Masters.

Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America’s best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession’s highest honors, the Plastic Surgery Foundation (PSF) Distinguished Service Award, which recognizes his contributions to education in plastic surgery. In addition, he has also been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations. He is also the recipient of the ASPS 2022 Honorary Citation.

Share article on social media or email:

GTMRx Shares New Report on Value of Implementing and Integrating Comprehensive Medication Management in Team-Based Care


News Image

“Payors and physicians are asking for evidence on the value and investing in CMM as they seek to offer value-driving services in primary care,” said Katherine H. Capps, co-founder and executive director at GTMRx.

Today, The Get the Medications Right™ (GTMRx) Institute, a coalition of over 1,700 members calling for medication management reform bringing together critical stakeholders across health care, is sharing its quick reference evidence document outlining the outcomes of implementing and integrating comprehensive medication management (CMM) in team-based care, including a review of the evidence of quality, access and costs. CMM is a patient-centered approach to optimizing medication use and improving patient health outcomes.

“With the third release of the GTMRx evidence document, we are encouraged to see quality literature being published surrounding CMM and the ability to improve care surrounding the quadruple aim,” said M. Shawn McFarland, PharmD, FCCP, BCACP, National Clinical Pharmacy Practice Program Manager Clinical Pharmacy Practice Office, Pharmacy Benefits Management Services, Veterans Health Administration. “This annual evidence document should strengthen the use case for CMM and continue to be a shining light of what our health care system can become.”

Each year in the United States, more than $528 billion is spent, and 275,000 lives are lost due to non-optimized medication use. Over 80% of Americans are taking one or more medications per week, and rates of hospital admissions resulting from medication-related problems continue to be on the rise — as a result, GTMRx is committed to providing awareness and a strategy to ensure that the industry works to “get the medications right” for all patients.

“Payors and physicians are asking for evidence on the value and investing in CMM as they seek to offer value-driving services in primary care,” said Katherine H. Capps, co-founder and executive director at GTMRx. “Using CMM is part of a “whole health” approach and is a missing ingredient essential to achieve medication optimization. Medication misuse, overuse, and underuse must be addressed as we seek to deliver accountable, affordable, and appropriate care.”

Key findings from the document highlight that regardless of the location, when CMM is integrated into team-based care, therapeutic goals are achieved, costs decrease, and the patient and provider experience improves. The CMM patient care process ensures each patient’s medications (whether prescription, nonprescription, alternative, traditional, vitamins, or nutritional supplements) are individually assessed to determine that each medication has an appropriate indication, is effective for the medical condition and achieves defined patient and clinical goals, is safe given the comorbidities and other medications being taken and that the patient can take the medication as intended and adhere to the prescribed regimen.

“The report showcases results from multiple settings and showcases one of the largest studies of patient experience (satisfaction) seeing a clinical pharmacist for CMM services at a Veterans Health Administration (VHA) facility, along with the impact of a pharmacogenomics-enriched CMM program in reducing health care costs,” said Marcia Buck, Pharm.D., FCCP, BCPPS and the director of clinical practice advancement for the American College of Clinical Pharmacy (ACCP). “It is our hope that by presenting the best of the published data from rigorous studies with increasingly larger patient samples, we will continue to drive the implementation of CMM in more practice sites until it becomes a routine component of team-based patient care.”

“We have long known that CMM can improve quality of care, reduce costs and improve the patient and provider experience,” added Capps. “Now we have evidence to show that when a clinical pharmacist, working in collaborative practice with a physician, uses CMM to identify, address, and mitigate the effects of adverse social determinants of health, they play a role in achieving the fifth component of the new quintuple aim of health care: health equity.”

To read the report, click here. And for more about the value of CMM, check out our explainer video.

About the Get the Medications Right™ Institute

The GTMRx Institute is a catalyst for change that brings critical stakeholders together, bound by the urgent need to get the medications right. We are physicians, pharmacists, nurses, patients, health IT innovators, drug and diagnostics companies, consumer groups, employers, and payers — aligned to save lives and save money through comprehensive medication management. We motivate practice transformation and push payment and policy reform by showcasing evidence and innovation. Together, we ACT to champion the appropriate, effective, safe, and precise use of medication and gene therapies. Learn more at gtmr.org. See the recently published GTMRx article in Health Affairs Forefront. Comprehensive Medication Management: A Missing Ingredient In Value-Based Payment Models | Health Affairs

###

Media Contact:

Aimee Eichelberger

Aimee (at) superior (dot) com

312.952.1528

Share article on social media or email:

WorkCare Acquires Corporate Health Resources to Expand Occupational Health Services and Provider Network


“The size, strength and enhanced offerings of WorkCare provide a bright future for CHR, particularly in the areas of information technology and human resources,” Cohen said.

WorkCare, Inc., a U.S.-based occupational health company, acquired Corporate Health Resources, Inc., (CHR), a nationwide occupational health examiner network service provider, effective Nov. 30, 2022, the companies announced today.

CHR will operate as a WorkCare company conducting business as usual as Corporate Health Resources, with the same team and existing service delivery model. Terms of the sale were not disclosed.

WorkCare supports employers with an integrated suite of solutions designed to protect and promote employee health and safety while meeting business objectives. CHR’s primary business is the provision of occupational health and medical surveillance exams via a provider network that spans the U.S. and extends to other countries.

“CHR is a natural fit for us,” said William E. Nixon, WorkCare’s President and Chief Executive Officer. “With the acquisition, we can further expand WorkCare’s medical provider network of 5,700-plus qualified providers, mutually nurture our client relationships, and access resources and expertise on both teams while allowing CHR to continue to operate with a considerable degree of autonomy.”

Peter P. Greaney, M.D., WorkCare’s founder, Executive Chairman and Chief Medical Officer, and CHR’s founder and President Karen Cohen, RHIA, say they have known and respected each other for many years.

“The size, strength and enhanced offerings of WorkCare provide a bright future for CHR, particularly in the areas of information technology and human resources,” Cohen said. “Finding a future home for CHR and our employees with a like-minded, quality-driven organization made the decision to sell to WorkCare an easy one.”

“I’ve long admired Karen Cohen’s professionalism and CHR’s firm commitment to customer service,” said Dr. Greaney. “I’m happy that she, and her employees, are now part of the WorkCare family so we can join forces to achieve our mutual goals.”

###

About WorkCare

WorkCare was established in 1984. Its integrated service lines include Medical Exams & Travel programs; Incident Intervention telehealth triage, Onsite Services & Clinic operations; Industrial Athlete interventions;

Consulting M.D.s; and Absence Management and Wellness Solutions. Based in Anaheim, Calif., the company employs clinicians and industry subject matter experts throughout the U.S. Visit http://www.WorkCare.com for more information.

About Corporate Health Resources

CHR was established as a woman- and veteran-owned business in 1986. In addition to its large provider network, CHR supports the administrative functions of internal corporate medical departments and facilitates the use of consulting medical directors at companies that do not have onsite medical staff. The company is based in Rockville, MD. Visit http://www.CHR.com for more information.

Share article on social media or email:

Clarion Safety Launches New Services and Solutions Online Hub for Manufacturing and Facility Professionals


Clarion Safety Systems knows that safety and compliance are constantly top of mind for machine builders and machine users – which is why they have launched their new Services & Solutions hub.

This new section of our website showcases these services, as well as the solutions that we offer more directly related to our physical label and sign products, such as full-service label/sign customization and a smart label-driven digital product management platform.

Clarion Safety Systems, a leading manufacturer of safety labels, signs, and tags, is pleased to announce the launch of a new ‘Services & Solutions’ online hub to help its OEM and workplace/EH&S professional customers clearly navigate the machine safety solutions and resources the company offers. The updated section of the site features new downloadable information related to risk and compliance as well as easy to browse categories of service offerings – helping industry professionals develop their machine safety and warnings programs with ease.

“While Clarion Safety is known for our core, best practice safety label products, as well as for our facility safety signs and custom industrial printing capabilities, in recent years, we’ve proudly expanded our offering to provide clients with additional value-added services. We now offer comprehensive machine safety, compliance, and risk assessment services for machine builders and machine users alike,” says Ron Crawford, CEO of Clarion Safety Systems.

“This new section of our website showcases these services, as well as the solutions that we offer more directly related to our physical label and sign products, such as full-service label/sign customization and a smart label-driven digital product management platform.”

Clarion Safety services and solutions include the following:


  • OEM Safety Solutions: These services are designed to help remedy safety and strategy issues that machine builders typically face from development to market. Clarion Safety provides full-service product safety and liability prevention capabilities, including risk assessments, manual audits, marking compliance – and more.
  • Workplace Safety Solutions: These services provide solutions to identify and manage hazards associated with machinery in the workplace. Clarion Safety’s TÜV-certified safety engineers provide machine safety, guarding, risk assessment, and training needs.
  • Label and Sign Services: In addition to their ready-made safety products, customers can receive optimized safety communication techniques, custom designs, and personalized best practice label and sign recommendations for both domestic and international warnings from Clarion Safety.
  • ClarionAccess®: This Clarion Safety solution takes product management to the next level by offering OEM end users a tool to digitally access all product-related information and resources instantly by scanning a QR code.
  • Purchasing Tools: With a focus on customer service, Clarion Safety offers a number of customer service and ordering related tools including rush orders and online quote requests.

Additional highlights of this new hub include:

  • Centralized Location for Ease of Access: This section of Clarion Safety’s site experienced a large overhaul to consolidate its machine safety services, product customizations, and purchasing tools into one easily accessible area.
  • New Services & Resources: In addition to their OEM focused solutions, Clarion Safety has also added a new area dedicated to EH&S and facility services, focusing on complex machinery as well as robots/cobots/automated machinery, fluid power safety systems, and functional safety systems. This section of the site features new downloadable safety resources and information sheets.
  • Modern Design: Along with transferring all services into one central location, Clarion Safety has also refreshed this section of its website’s design and navigation for an improved user experience.

As a company, Clarion Safety is a longstanding and active member of both the U.S. and international standards bodies responsible for safety signs and labels. For over 30 years, Clarion Safety has been a member of the ANSI Z535 committee, and for over 20 years, has been a member of ISO/TC 145, a key international safety sign and label standards-writing committee, and the one tasked with standardizing symbols in the ISO 7010 library. Through their long list of safety credentials and standards body members, they are able to consistently develop and enhance machinery and facility services for the industrial community. Their comprehension machinery safety services are also accompanied by an immense collection of best practice safety labels, signs, and tags that are all designed and customizable to ANSI and ISO standards.

To learn more about Clarion Safety and its history in the field of visual safety communication, visit the company’s website.

Clarion Safety also accepts media inquiries and speaking opportunities related to safety and risk. To submit a media inquiry, visit the company’s “Newsroom” and scroll to the “For the Media” section.

ABOUT CLARION SAFETY SYSTEMS

Clarion Safety Systems, LLC, is the leading designer and manufacturer of visual safety solutions that help customers in more than 180 industries worldwide to make their products and premises safer. Clarion Safety offers a full range of standard and custom products including machinery safety labels, environmental and facility safety signs, pipe and valve identification markings, lockout/tagout products, and safety-grade photoluminescent egress path-marking escape systems. The company also provides complementary services for comprehensive machine safety, compliance and risk reduction. Founded in 1990, Clarion Safety continues to play a leading role in the development and writing of international and national standards for safety signs, labels, and markings. It is headquartered at 190 Old Milford Road in Milford, PA, 18337, and online at http://www.clarionsafety.com.

Share article on social media or email:

New Study Shows Comprehensive Genomic Evidence is Critical for Calculating Rare Disease Prevalence


News Image

“The ENPP1 genomic landscape provided by Genomenon has enriched our understanding of this genetic disorder and continues to inform our research and clinical trial design.” – Catherine Nester, Vice President of Physician and Patient Strategies, Inozyme Pharma

Genomenon, Inc., an AI-driven genomics company, today announced the publication of a paper in the Orphanet Journal of Rare Diseases that calculates the prevalence of ENPP1 deficiency—a disease claiming more than half of all infants within the first few months of life—to be more than triple the prior estimate. The study, conducted by the Genomenon scientific team and leading disease experts from the National Institutes of Health (NIH) and Münster University Children’s Hospital, highlights a core strength of Genomenon’s rigorous methodology for identifying and classifying genetic data needed to improve rare disease prevalence calculations.

“More accurate prevalence estimates for rare diseases are essential, as they not only justify investment in life-saving therapies, but also help pharma R&D and commercial teams successfully bring them to market,” said Genomenon Chief Scientific Officer and co-founder Mark Kiel, MD, PhD. “Discovery of this higher prevalence rate aptly demonstrates how our exhaustive knowledgebase of expertly curated genomic evidence supports pharmaceutical companies that are pioneering development of therapies for orphan diseases.”

Traditional methods for estimating prevalence rely on clinical data, which can be unreliable for rare diseases such as ENPP1 deficiency that are difficult to diagnose. Although genetic data has been used to calculate disease prevalence, the accuracy of results is dependent on the completeness of the knowledgebase of causative variants and number of healthy individuals within the population database. In this paper, the authors used Genomenon’s AI-powered technology to reveal a much broader set of ENPP1 pathogenic variants than previously known. This data significantly increased the estimate of genetic prevalence—and results suggest that many affected individuals remain undiagnosed.

“This revised estimate underscores the urgent unmet medical need for effective therapies for patients with ENPP1 deficiency,” said Catherine Nester, Vice President of Physician and Patient Strategies at Inozyme Pharma (NASDAQ: INZY), a clinical stage rare disease biopharmaceutical company currently developing novel therapeutics for the treatment of pathologic mineralization disorders. “The ENPP1 genomic landscape provided by Genomenon has enriched our understanding of this genetic disorder and continues to inform our research and clinical trial design.”

Read the paper: “Estimation of ENPP1 Deficiency Genetic Prevalence Using a Comprehensive Literature Review and Population Database”

About Genomenon

Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.

For more information, visit Genomenon.com and follow us on LinkedIn and Twitter.

About ENPP1 Deficiency

ENPP1 Deficiency is a progressive condition that manifests as a spectrum of diseases. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI), which is characterized by extensive vascular calcification and neointimal proliferation (overgrowth of smooth muscle cells inside blood vessels), resulting in myocardial infarction, stroke, or cardiac or multiorgan failure. Approximately 50% of infants with ENPP1 Deficiency die within six months of birth. Children with ENPP1 Deficiency typically experience rickets, a condition also known as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adults experience osteomalacia (softened bones), and they can exhibit a range of signs and symptoms that include hearing loss, arterial calcification, and cardiac and/or neurological involvement. There are no approved therapies for ENPP1 Deficiency.

Share article on social media or email:



UT Health San Antonio, Ohio company reach license agreement to develop…


Research from The University of Texas Health Science Center at San Antonio suggests a novel vaccine against the sexually transmitted infection chlamydia. Discoveries made at the health science center…

(PRWeb December 14, 2022)

Read the full story at https://www.prweb.com/releases/ut_health_san_antonio_ohio_company_reach_license_agreement_to_develop_chlamydia_vaccine/prweb19076305.htm

Catalent to Expand Its Biologics Analytical Services with New Facility…


Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today…

(PRWeb December 14, 2022)

Read the full story at https://www.prweb.com/releases/catalent_to_expand_its_biologics_analytical_services_with_new_facility_in_durham_north_carolina/prweb19075643.htm